Company news

Evaxion A/S news in 2026

Evaxion A/S's news releases, calls and decks from 2026, newest first.

View company

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 23, 2026

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 19, 2026

Decks in 2026